SECURITIES & EXCHANGE COMMISSION EDGAR FILING GUI
Post# of 117
(Total Views: 298)
Posted On: 05/15/2019 4:51:44 PM
SECURITIES & EXCHANGE COMMISSION EDGAR FILING
GUIDED THERAPEUTICS INC
Form: NT 10-Q
Date Filed: 2019-05-15
Corporate Issuer CIK: 924515
© Copyright 2019, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number 000-22179
(Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR
For Period Ended: March 31, 2019
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________
Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
_______________________________________________
PART I
REGISTRANT INFORMATION
Full Name of Registrant: Guided Therapeutics, Inc.
Address of Principal Executive
Office (Street and number): 5835 Peachtree Corners East, Suite D
City, State and Zip Code: Norcross, Georgia 30092
1
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
PART II
RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X]
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or
portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR or the transition report or portion thereof, could not be filed
within the prescribed time period.
The registrant’s quarterly report on Form 10-Q could not be filed within the prescribed time period (the registrant also late filed its annual 10-K report for 2018
and 2017 and quarterly 10-Q reports in 2018). During the three months ended March 31, 2019, the registrant continued to experience considerable financial
constraints. These financial constraints have postponed the ability of the registrant’s auditors from performing review procedures and in starting the financial
review process and thus resulted in delays in the preparation and presentation of financial information. These delays contributed to the registrant’s inability to
process and review the financial information required to file the quarterly report and complete its review on Form 10-Q by the date required without incurring
undue hardship and expense.
The registrant will make every effort to file its Form 10-Q within the permitted extension period.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
Gene S. Cartwright (770) 242-8723
(Name) (Area Code) (Telephone Number)
2
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify
report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the
results cannot be made.
Guided Therapeutics, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 15, 2019 By: /s/ Gene S. Cartwright
Gene S. Cartwright
President and Chief Executive Officer
GUIDED THERAPEUTICS INC
Form: NT 10-Q
Date Filed: 2019-05-15
Corporate Issuer CIK: 924515
© Copyright 2019, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number 000-22179
(Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR
For Period Ended: March 31, 2019
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________
Nothing in the form shall be construed to imply that Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
_______________________________________________
PART I
REGISTRANT INFORMATION
Full Name of Registrant: Guided Therapeutics, Inc.
Address of Principal Executive
Office (Street and number): 5835 Peachtree Corners East, Suite D
City, State and Zip Code: Norcross, Georgia 30092
1
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
PART II
RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X]
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or
portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR or the transition report or portion thereof, could not be filed
within the prescribed time period.
The registrant’s quarterly report on Form 10-Q could not be filed within the prescribed time period (the registrant also late filed its annual 10-K report for 2018
and 2017 and quarterly 10-Q reports in 2018). During the three months ended March 31, 2019, the registrant continued to experience considerable financial
constraints. These financial constraints have postponed the ability of the registrant’s auditors from performing review procedures and in starting the financial
review process and thus resulted in delays in the preparation and presentation of financial information. These delays contributed to the registrant’s inability to
process and review the financial information required to file the quarterly report and complete its review on Form 10-Q by the date required without incurring
undue hardship and expense.
The registrant will make every effort to file its Form 10-Q within the permitted extension period.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
Gene S. Cartwright (770) 242-8723
(Name) (Area Code) (Telephone Number)
2
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify
report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the
results cannot be made.
Guided Therapeutics, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 15, 2019 By: /s/ Gene S. Cartwright
Gene S. Cartwright
President and Chief Executive Officer
(0)
(0)Guided Therapeutics, Inc. (GTHP) Stock Research Links
WORDS TO LIVE BY:
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.